| Name | Title | Contact Details |
|---|
Sure-Response, Inc. is an independently owned and operated manufacturer and dealer specializing in staff communications and notification needs for the healthcare, retail and hospitality markets. Sure-Response provides unique product offerings from both our own proprietary line of products as well as partnerships formed with other manufacturers. By focusing on providing commercial grade hand held two-way radios that improves staff to staff communication, we have established our own brand in two-way radio market niches. Our company was founded in 2008 to not only to develop proprietary staff to staff communications tools but also to address the demand from pager to radio while combining with the nursing call system to improve patient safety and care. Our Radio Integration System allows for alarm notifications to come across our many brands of digital and analog radios, enabling staff to communicate efficiently thus eliminating the need for overhead paging. This invention improves the patients safety in senior care facilities. Now staff can communicate effectively while minimizing the number of devices they have to carry.
TIXiMED, Inc. is focused on developing and commercializing TXNIP inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 diabetes. TIXiMED is the exclusive license holder for the patent (composition of matter and method of use) surrounding TIX100, a novel small molecule that normalizes pancreatic beta cell TXNIP, a detrimental protein elevated in Type 1 and Type 2 diabetes. Increased TXNIP causes pancreatic islet dysfunction and death of insulin-producing beta cells and thereby contributes to the development and progression of diabetes. Diabetes affects more than half a billion people worldwide. Those affected by Type 1 diabetes are dependent on multiple daily insulin injections or continuous insulin infusions to stay alive and manage their blood sugar. Oral anti-diabetic drugs are only approved for Type 2 diabetes, but can be associated with multiple side effects, underlining the need for novel and better oral diabetes medications for Type 1 and Type 2 diabetes. TXNIP inhibition has recently been demonstrated to be an effective and safe therapeutic approach in adults and children with recent onset Type 1 diabetes and TIX100 shows beneficial, anti-diabetic effects in 4 different mouse models. Advantages of TIX100 include oral availability, no associated hypoglycemia or weight gain, potent inhibition of detrimental TXNIP in human islets, and a favorable pharmacokinetic and safety profile. In addition, TIX100 inhibits excessive glucagon secretion and hepatic glucose production and protects against fatty liver. Thus, TIX100 holds promise for durable, weight-neutral improvement in glycemic control in Type 1 and Type 2 diabetes by targeting common underlying pathology and promoting patients own islet cell health.
Jefferson Consulting Group, LLC is a Washington, DC-based company in the Business Services sector.
Alpha State Productions, The is a Glen Burnie, MD-based company in the Business Services sector.